Eagle Medium (DMEM, high glucose). Media contained 10% heat inactivated FCS, Lglutamate (2 mM) and 100 U ml -1 penicillin and 100 µg ml -1 streptomycin. Cells were routinely trypsinized and reseeded twice per week. For the experiments, cells were seeded in plastic dishes and incubated with the respective compounds in the medium at 37°C and 5% CO2. For studies of C3-mediated effects in cells, the pictures of the cells were taken after the indicated incubation periods with the toxins using an Axiovert 40CFl microscope from Zeiss (Oberkochen, Germany) connected to a progress C10 CCD camera from Jenoptik (Jena, Germany). For internalization studies into cells, images were obtained using a LSM 710 laser scanning confocal microscope (LCSM) system (Zeiss, Germany) coupled to XL-LSM 710 S incubator and equipped with a 63x oil immersion objective. The acquired images were processed with ImageJ software (NIH, Bethesda). For in vivo experiments, A549-Red-Fluc cells (Perkin Elmer, BW119266) were cultured in RPMI 1640 supplemented with 10% heatinactivated FCS and puromycin (2 µg ml -1 ).
Cellular uptake studies of transport proteins, SST(N)-Avi. A549 cells were pre-cultured in high glucose DMEM medium fortified with 10% fetal bovine serum, 1%
penicillin/streptomycin and seeded at 6,500 cells/well in a white 96-well (half-area) plate. The cells were left to adhere overnight at 37°C, 5% CO2. The media were removed and different concentrations of the transporters SST(N)-Avi (50 nM, 100 nM, 200 nM, 500 nM) in 50 μl DMEM were added into each well. Avi was added as a control. The treated cells were subsequently incubated separately for 4 h at 37°C, 5% CO2. After incubation, the cells were washed (3 times) with Dulbecco's PBS buffer to remove non-specific binding followed by incubating the cells for a further 24 h in 50 μl per well of cell lysis buffer. Emission measurements (λex = 558 nm, λem = 585 nm) were recorded using TECAN M1000 microplate reader to determine the uptake efficiencies. The values were given as mean ± SD (n=4) and data were analyzed by one-way analysis of variance (ANOVA) with Bonferroni correction for multigroup comparison at *p<0.05, NS = not significant. with Origin Pro 9.1. in 300 µl DMEM medium with 10% FCS. The cells were cultured overnight to allow adhesion at 37°C, 5% CO2. Subsequently, the medium was removed and 2 µM of Avi and SST4-Avi were added, respectively. The cells were then further incubated for 4 h at 37°C, 5% CO2. Before imaging, cells were washed with DMEM medium for 3 times. Cell membrane was stained with 0.5 μl of CellMask Deep Red (0.5 mg ml -1 , ex/em: 649/666) for 5 min. The live cell imaging was performed using a LSM 710 laser scanning confocal microscope system (Zeiss, Germany)
coupled to an XL-LSM 710 S incubator and equipped with a 63x oil immersion objective. The emission of SST4-Avi was recorded using a 525-759 nm filter and a 514 nm argon laser for excitation. The acquired images were processed with ZEN 2011 software ( Figure S2 ). Internalization of SST3-Avi into different cancer cell types. SSTR2-positive A549 and LiSa-2 cells as well as SSTR2-negative SK-UT1-cells were seeded in 8-well plates (ibidi GmbH, Munich, Germany) with a density of 30,000 cells per well in 300 µl. The cells were incubated at 37°C and 5% CO2 for 24 h. SST3-Avi (fluorescein-labeled) with a final concentration of 400 nM was added to a total volume of 300 µl. As control, cells were treated only with DMEM.
After 24 h, the cells were washed with PBS and reconstituted with complete DMEM and imaging was performed using LSCM. Scale bars correspond to 10 µm.
Expression and purification of the Cys-mutant C3bot1-A1C. To insert a cysteine-mutation, we constructed a mutant of C. botulinum C3bot1-exoenzyme by site-directed mutagenesis using appropriate PCR primers. By doing so, we replaced Ala-1 by cysteine. Afterwards, the enzymatically active C3bot mutant C3bot1-A1C (Cys-C3) was overexpressed as GST-tagged protein and purified by affinity chromatography. E. coli BL21 transformed with pGEX2T-CysC3bot1 were grown in Luria-Bertani medium at 37°C to an optical density of 0.6 -0.8. The LB-medium was added with 100 µg ml -1 ampicillin. After reaching the desired optical density, ng of C3bot1 for control were subjected to SDS-PAGE followed by Western blotting.
Expression of the protein was confirmed by detecting with a specific antibody against C3bot1.
(c) J774A.1 macrophage-like cells were treated for 6 h with either C3bot1-A1C (3 µg ml -1 ), C3bot1 (3 µg ml -1 ) or were left untreated (control) and C3-induced morphological changes were recorded to demonstrate biological activity of the proteins.
Scheme S1. Synthesis of compound 1. 
Synthesis of biotinylhydrazine linker (1)
.
Biotinylation of C3 (B-C3).
Recombinant cysteine mutant of C3 was expressed and purified in E. coli BL21 as described above. 60 μl of HEPES (100 mM, pH 7. were acquired using a Malvern Nano Zetasizer over min. 10 runs. As a control, the zetapotential of a solution with final concentration of 0.5 mg/mL human serum albumin (pI < 5) was determined. Table S1 . Zeta values of Avi, C3 and SST3-Avi-C3 using Malvern Zetasizer. GmbH (Fig. S8) .
After 18 h, the solutions prepared above were aliquoted (5 µl) and 0.2 µl of 1 M HCl was added to each solution for acidification. MST measurements were obtained after 4 h and there was no binding observed (Fig. S8, blue) , which indicated the acid-induced C3 release.
A similar procedure was repeated for B-C3 in pH 4 buffer as a negative control and no binding was observed upon incubation with SST3-Avi (Fig. S8, magenta) . human serum was also analyzed with and without heating as described above as control. The gel was then blotted on a nitrocellulose membrane and biotinylated components were detected using streptavidin/peroxidase conjugate to determine the stability of SST3-Avi-C3. Native PAGE was not feasible for quantification due to the positive pI of avidin. The CAM model represents a very suitable system because the capillary network of the CAM is prone to new blood vessel formation, which is essential for the embryonic gas exchange.
Therefore, the CAM model has been recommended by the United States Food and Drug Administration (FDA) as preclinical model for in vivo studies on angiogenesis. further incubated and after 24 h incubation, the cell viability was measured by MTS assay. Data are given as mean ± SD of triplicates.
